Evidence map›Paper›PMID 35989092›Full record

ArticleClinical and molecular hepatology2023

Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B.

Lung-Yi Mak, Danny Wong, Alison Kuchta, Martina Hilfiker, Aaron Hamilton, Ning Chow, XianHua Mao, Wai Kay Seto, Man-Fung Yuen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and molecular hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Lower Serum HBV RNA Level is Associated with Liver Cirrhosis in Patients Treated with Nucleos(t)ide Analogs: A Population-Based Cross-Sectional Study.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. [Research progress of biomarkers of hepatitis B virus and clinical significance].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2023
    Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Lung-Yi MakDepartment of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong.
Danny WongDepartment of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong.
Alison KuchtaRoche Molecular Systems, Inc., Pleasanton, CA, USA.
Martina HilfikerRoche Diagnostics Int. AG, Rotkreuz, Switzerland.
Aaron HamiltonRoche Molecular Systems, Inc., Pleasanton, CA, USA.
Ning ChowDepartment of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong.
XianHua MaoDepartment of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong.
Wai Kay SetoDepartment of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong.
Man-Fung YuenDepartment of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong.
Chinese University of Hong Kong · HKRoche (Switzerland) · CH

Funding

Research Grants Council, The Government of the Hong Kong Special Administrative Region 17108921
6 · The paper itself

Abstract

BACKGROUND/

aimsWe investigated the dynamics of serum HBV pre-genomic RNA (pgRNA) and hepatitis B core-related antigen (HBcrAg) in patients receiving nucleos(t)ide analogues (NAs) and their predictability for favourable suppression of serum hepatitis B surface antigen (HBsAg).

methodsSerum viral biomarkers were measured at baseline, weeks 4, 12, 24, 36, and 48 of treatment. Patients were followed up thereafter and serum HBsAg level was measured at end of follow-up (EOFU). Favourable HBsAg response (FHR) was defined as ≤100 IU/mL or HBsAg seroclearance upon EOFU.

resultsTwenty-eight hepatitis B e antigen (HBeAg)-positive and 36 HBeAg-negative patients (median, 38.2 years old; 71.9% male) were recruited with median follow-up duration of 17.1 years (interquartile range, 12.8-18.2). For the entire cohort, 22/64 (34.4%) achieved FHR. For HBeAg-positive patients, serum HBV pgRNA decline at week 4 was significantly greater for patients with FHR compared to non-FHR (5.49 vs. 4.32 log copies/mL, respectively; P=0.016). The area under the receiver-operating-characteristic curve (AUROC) for week 4 HBV pgRNA reduction to predict FHR in HBeAg-positive patients was 0.825 (95% confidence interval [CI], 0.661-0.989). For HBeAg-negative patients, instead of increase in serum HBcrAg in non-FHR patients, FHR patients had median reduction in HBcrAg at week 4 (increment of 1.75 vs. reduction of 2.98 log U/mL; P=0.023). The AUROC for week 4 change of HBcrAg to predict FHR in HBeAg-negative patients was 0.789 (95% CI, 0.596-0.982).

conclusionEarly on-treatment changes of serum HBV pgRNA and HBcrAg at 4 weeks predict HBsAg seroclearance or ≤100 IU/mL in NA-treated CHB patients upon long-term FU.

Indexed as

Hepatitis B, ChronicHepatitis B virusAdultAntiviral AgentsBiomarkersDNA, ViralFemaleGenomicsHepatitis B Core AntigensHepatitis B e AntigensHepatitis B Surface AntigensHumansMaleRNAAntiviral AgentsBiomarkersDNA, ViralHepatitis B Core AntigensHepatitis B e AntigensHepatitis B Surface AntigensRNAChronic hepatitis BHepatitis B core antigenHepatitis B e antigenTreatment outcomeViremia

Identifiers

PMID35989092
PMCPMC9845664
OpenAlexW4292246852

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.